FOXP3 and neoplasm: IDO inhibits natural and therapy‐induced antitumour immunity as it catabolises the amino acid tryptophan to generate kynurenine and other immunosuppressive catabolites which activate Foxp3 regulatory T cells and attenuate effector T‐cell responses to inhibit immune‐mediated killing of tumour cells.